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IL-10 expression in human Th1 cells
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Ceri A. Roberts2,14, Zoe Hall5, Gaelle LeFriec6, Kevin A. Robertson7, Paul Lavender8,
Jens Gammeltoft Gerwien4,15, Leonie S. Taams 2, Julian L. Grifﬁn5, Emanuele de Rinaldis3,
Lisa G.M. van Baarsen9,10, Claudia Kemper6,11,12, Peter Ghazal7,13 & Andrew P. Cope 1,2
The mechanisms controlling CD4+ T cell switching from an effector to an anti-inﬂammatory
(IL-10+) phenotype play an important role in the persistence of chronic inﬂammatory dis-
eases. Here, we identify the cholesterol biosynthesis pathway as a key regulator of this
process. Pathway analysis of cultured cytokine-producing human T cells reveals a signiﬁcant
association between IL-10 and cholesterol metabolism gene expression. Inhibition of the
cholesterol biosynthesis pathway with atorvastatin or 25-hydroxycholesterol during switch-
ing from IFNγ+ to IL-10+ shows a speciﬁc block in immune resolution, deﬁned as a signiﬁcant
decrease in IL-10 expression. Mechanistically, the master transcriptional regulator of IL10 in
T cells, c-Maf, is signiﬁcantly decreased by physiological levels of 25-hydroxycholesterol.
Strikingly, progression to rheumatoid arthritis is associated with altered expression of cho-
lesterol biosynthesis genes in synovial biopsies of predisposed individuals. Our data reveal a
link between sterol metabolism and the regulation of the anti-inﬂammatory response in
human CD4+ T cells.
https://doi.org/10.1038/s41467-019-08332-9 OPEN
1 Academic Department of Rheumatology, King’s College London, London SE1 1UL, UK. 2 Department of Inﬂammation Biology, School of Immunology and
Microbial Sciences, Centre for Inﬂammation Biology and Cancer Immunology, King’s College London, London SE1 1UL, UK. 3 National Institute for Health
Research Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London SE1 9RT, UK. 4Global Drug
Discovery, Novo Nordisk A/S, 2880 Bagsvaerd, Denmark. 5 Department of Biochemistry and the Cambridge Systems Biology Centre, University of
Cambridge, Cambridge CB2 1QW, UK. 6MRC Centre for Transplantation, King’s College London, London SE1 9RT, UK. 7 Division of Infection and Pathway
Medicine, University of Edinburgh, Edinburgh EH16 4SB, UK. 8 School of Immunology and Microbial Sciences, King’s College London, London SE1 9RT, UK.
9Amsterdam Rheumatology and immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Amsterdam UMC, University of
Amsterdam, 1105 AZ Amsterdam, Netherlands. 10 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ
Amsterdam, Netherlands. 11 Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National
Institutes of Health (NIH), Bethesda, MD 20892, USA. 12 Institute for Systemic Inﬂammation Research, University of Lübeck, 23562 Lübeck, Germany.
13 Systems Immunity Research Institute, Medical School, University of Cardiff, Cardiff CF14 4XN, UK. 14Present address: Cellular and Molecular Therapy, NHS
Blood and Transplant, Bristol BS34 7QH, UK. 15Present address: Rheumatology NEC, Eli Lilly, 2730 Copenhagen, Denmark. Correspondence and requests for
materials should be addressed to E.P. (email: esperanza.perucha@kcl.ac.uk) or to A.P.C. (email: andrew.cope@kcl.ac.uk)
NATURE COMMUNICATIONS |          (2019) 10:498 | https://doi.org/10.1038/s41467-019-08332-9 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
CD4
+ T-helper (Th) effector cells are integral to the
immune response, differentiating into Th1, Th2 and
Th17 subsets tuned to respond to a wide range of
pathogens and environmental insults1,2. Th1 cells produce the
signature cytokine interferon-γ (IFNγ) that functions to efﬁ-
ciently eradicate intracellular pathogens. While defects in the
IFNγ pathway lead to uncontrolled infection3,4, Th1 responses
must be tightly controlled to prevent host tissue damage following
pathogen elimination. The restoration of immune homeostasis
can be deﬁned by the expression of interleukin-10 (IL-10), a
prototypic anti-inﬂammatory cytokine that orchestrates termi-
nation of immune responses2,5–7. The absence of this regulatory
checkpoint may lead to persistent inﬂammatory responses, while
uncontrolled expression of IL-10 may impede eradication of
infectious organisms8,9. Despite its importance, our under-
standing of the molecular switches that control how CD4+ T cells
acquire the capacity to produce IL-10 remains incomplete.
Cytokines such as IL-12, IL-27 or type I IFN in combination with
T cell receptor and co-stimulatory receptor engagement have
been shown to induce IL-1010–12. These signals are propagated
via downstream signalling intermediates (extracellular signal-
regulated kinase (ERK), nuclear factor for activated T cells
(NFAT) and nuclear factor-κB (NF-κB)) and induce expression of
c-Maf, a master regulator of IL10 in T cells and, together with
other transcription factors such as IRF4, AhR or Blimp-1, activate
the transcription of IL1010,11,13–17. These studies indicate a high
level of complexity in IL-10 regulation.
We have developed in vitro models of human T cell activation
and differentiation that have allowed us to elucidate more pre-
cisely the pathways that promote IL-10 expression. In humans, a
range of studies have provided evidence that the autocrine
engagement of CD46 by complement is critically important for
IFNγ secretion and Th1 induction, and, together with IL-2
receptor signalling, induces a switch to IL-10 co-production in
Th1 cells with a transition into a self-regulatory, contracting
phase5. Accordingly, patients deﬁcient in CD46 cannot generate
Th1 responses and suffer from recurrent infections18,19, while
dysregulation in this CD46/IL-2R crosstalk leads to a reduced IL-
10 switching and hyperactive Th1 responses in rheumatoid
arthritis (RA) and multiple sclerosis18,20.
To meet the energy demands required for T cell effector
function, T cell activation is accompanied by a metabolic shift
from oxidative phosphorylation to aerobic glycolysis, allowing
increased metabolic ﬂux towards anabolic pathways in order to
provide key metabolites required for the acquisition of effector
function21. This activation-induced metabolic reprograming is
coordinated by canonical metabolic signals, such as mammalian
target of rapamycin, and immune speciﬁc cytokines and tran-
scription factors21,22, as well as the complement receptor CD4622,
and has been extensively studied in recent years23. Notably, this
metabolic reprogramming also involves changes in the cholesterol
biosynthesis pathway (CBP)24, although much less is known
about its involvement in the regulation of immune function. In
keeping with a metabolic requirement for T cell activation, sig-
nalling via the T cell receptor enhances cholesterol metabolism by
increasing the transcription of key enzymes of the CBP25.
Moreover, alterations in the expression of liver X receptor-β and
sterol regulatory element-binding protein 2 (SREBP-2), which
fundamentally perturbs the integrity of cholesterol biosynthesis,
have a direct impact on T cell proliferation and effector
functions25,26, while inhibition of mevalonate metabolism in T-
regulatory cells (Tregs) has been shown to block their suppressive
capacity27. In addition to this, the CBP generates not only cho-
lesterol, an essential building block of cellular membranes, but it
also provides metabolites with known roles in cellular and
immunological processes. For example, the pathway generates
non-sterol mevalonate derivatives such as farnesol and ger-
anylgeraniol, implicated in the post-transcriptional prenylation of
intracellular proteins such as Rho and Ras24. It also synthesises 7-
dihydrocholesterol, the precursor of immunomodulatory vitamin
D3, which has been directly implicated in IL-10 production by
CD4+ T cells28. The CBP also generates oxysterols, derivatives of
cholesterol such as 25-hydroxycholesterol (25-HC), that is part of
the type I IFN anti-viral response29,30, and 7-ketocholesterol, a
natural ligand for the transcription factor AhR31, which is also
implicated in IL-10 gene expression in Tr1-like cells15.
In the present study, we demonstrate that targeted perturbation
of the CBP in human CD4+ T cells blocks the switch from
effector (IFNγ+) to regulatory (IL-10+) function and has a direct
and highly speciﬁc impact on IL-10 messenger RNA (mRNA)
and protein levels. Furthermore, cholesterol pathway blockade
downregulates the expression of the transcription factor c-Maf.
Moreover, transcript levels of key enzymes belonging to the CBP
are signiﬁcantly related to disease progression in subjects at high
risk of developing RA, providing an in vivo correlation to our
model. Our work provides the ﬁrst evidence of lipid metabolism
regulating the contraction of the human CD4+ T cell response
and offers new insights into the complex relationship between
lipid metabolism, inﬂammatory disease and host immunity.
Results
Th1 switching to IL-10 is linked to cholesterol biosynthesis.
Upon activation with α-CD3 and α-CD46, CD4+ Th1 cells
undergo a self-regulatory cycle during which IFNγ+ cells co-
express IL-10, followed by an IL-10 single-positive regulatory
phase, creating a Th1 switching cycle18. To unravel the molecular
mechanisms controlling the expression of IL-10 during
Th1 switching, we stimulated human peripheral blood CD4+
T cells with α-CD3 and α-CD46 for 36 h to generate cells at
different phases of the Th1 switching cycle, as previously
described18. Double-negative IFNγ−IL-10−, single-positive
IFNγ+IL-10− and IFNγ-IL-10+ cells and double-positive
IFNγ+IL-10+ subsets were puriﬁed by cell sorting and sub-
jected to gene expression proﬁling (Supplementary Figure 1a and
b). Initial clustering analysis revealed that populations did not
segregate based on their gene expression (Supplementary Fig-
ure 1c). We reasoned that genes involved in the regulation of IL-
10 expression would be present in the pre-IL-10 expression
phases of the cycle (IFNγ−IL-10−, IFNγ+IL-10− subsets, black
gates, Fig. 1a) and that their expression might correlate with IL-10
protein levels in the double-positive population (blue gate,
Fig. 1a). To test this, datasets were interrogated for genes present
in either the double-negative or IFNγ+IL-10− subsets whose
expression correlated with IL-10 expression in the double-positive
population. Levels of IL-10 protein were quantiﬁed by ﬂow
cytometry using median ﬂuorescence intensity (MFI) as an
indicator of the number of IL-10 molecules per cell, and nor-
malised to the MFI value of the double-negative population to
account for inter-experimental variability. Using this approach we
identiﬁed 111 genes expressed in both the double-negative and
single-positive IFNγ+IL-10− populations correlating inversely
(top) or directly (bottom) with IL-10 levels (Fig. 1b and Sup-
plementary Data 1). From these gene sets, Ingenuity Pathway
Analysis (IPA) ranked multiple pathways linked to cholesterol
biosynthesis as being the most signiﬁcantly associated with IL-10
expression (Fig. 1c). IPA analysis also revealed an inverse rela-
tionship between genes belonging to the CBP expressed by the
pre-IL-10 populations and IL-10 protein levels in the double-
positive IFNγ+IL-10+ population, suggesting that active choles-
terol biosynthesis might be required to license Th1 cells to express
IL-10. This signal was further validated by quantitative real-time
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PCR (qPCR) for selected genes within the CBP (Supplementary
Figure 1d).
CD46 signals through one of two intracellular cytoplasmic tails:
CYT-1 promotes Th1 IFNγ expression, while CYT-2 promotes
IL-10 switching18. To further investigate the link between
cholesterol biosynthesis and IL-10 expression, we compared the
transcriptome of Jurkat T cells stably expressing CYT-1 or CYT-
2; the transcriptome of untransduced Jurkat T cells was used as
control. Principal component analysis (PCA) identiﬁed three
distinct subpopulations (Supplementary Figure 1e), indicating
that signalling through either CYT-1 or CYT-2 tails was sufﬁcient
to drive distinct transcriptional proﬁles. Once again, IPA of
differentially expressed genes identiﬁed cholesterol biosynthesis
and related biosynthetic pathways (mevalonate and geranyldi-
phosphate) as highly enriched (Fig. 1d). Moreover, and as
observed in Th1 switching primary CD4+ T cells, these genes
were downregulated in Jurkat T cells expressing CYT-1 (effector)
when compared to CYT-2 (regulatory)-expressing cells. Together,
these results indicate that Th1 switching to IL-10 expression is
directly linked to the CBP, and that populations expressing IL-10
have higher levels of CBP-related genes when compared to IL-10-
negative populations.
Inhibition of the mevalonate pathway blocks Th1 switching. To
functionally assess the relationship between cholesterol bio-
synthesis and the generation of IL-10-expressing T cells, we
blocked cholesterol biosynthesis during Th1 switching by treating
cell cultures with atorvastatin, a synthetic lipid-lowering statin
that competitively inhibits HMG-CoA reductase, one of the ﬁrst
steps of the mevalonate pathway (Supplementary
Figure 2). Atorvastatin inhibited the generation of both IL-10-
expressing double-positive (IFNγ+IL-10+) and single-positive
(IFNγ−IL-10+) cells in a dose-dependent manner, while the
frequency of IFNγ+IL-10− cells was increased (Fig. 2a, b and
Supplementary Figure 3 for gating strategy), indicating that statin
treatment blocks Th1 switching to IL-10. Inhibition of IL-10
levels in statin-treated cultures was prevented by supplementation
with mevalonic acid (MA), conﬁrming the speciﬁcity of this
effect, and arguing against off-target effects of the pharmacolo-
gical inhibitor. Measurement of IL-10 secretion after 36 h of
culture produced similar results (Fig. 2c). It is noteworthy that
atorvastatin had only a modest effect on the MFI of IL-10 in
residual populations of IL-10-expressing cells (Supplementary
Figure 4a), suggesting again that statins primarily block the
transition from IFNγ to IL-10-producing cells, rather than
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Fig. 1 Metabolic regulation of T-helper type 1 (Th1) switching in primary human CD4+ T cells. a Schematic ﬂow cytometric dot-plot of the life cycle of
human Th1 switching; double-positive cells are highlighted with a blue gate, while IL-10-negative populations are shown within a black gate; b Heatmap of
111 signiﬁcantly expressed genes in the double-negative (IFNγ−IL-10−) and single-positive (IFNγ+IL-10−) populations associated with changes in IL-10
protein expression, as measured by median ﬂuorescence intensity ratio (MFI+:MFI−) for IL-10 expression in the double-positive (IFNγ+IL-10+) population.
c Ingenuity Pathway Analysis (IPA) based on genes from b (SP: superpathway). Bars represent the percentage of the number of genes mapping to a
particular pathway, coloured in green to note the inverse correlation. The number indicates the number of total genes ascribed to the pathway. The yellow
line represents the P value as calculated by Fisher’s test and corrected for multiple testing using the Benjamini–Hochberg correction. d IPA based on genes
differentially expressed between CYT-1- and CYT-2-expressing Jurkat T cells and analysed and annotated as in c
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08332-9 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:498 | https://doi.org/10.1038/s41467-019-08332-9 |www.nature.com/naturecommunications 3
regulating levels of IL-10 within existing populations of IL-10-
expressing T cells. Moreover, a reduction in IL10 mRNA
expression following statin treatment was detected (Fig. 2d),
pointing to a link between CBP and the transcriptional regulation
of IL-10 expression. In our experimental conditions, atorvastatin
did not induce changes in cell apoptosis or viability (Supple-
mentary Figure 4b and 4c), nor could we detect cell proliferation
at the 36 h time point, ruling out the possibility that reduced
rates of cell proliferation by atorvastatin accounted for the
changes in IL-10 expression (Supplementary Figure 4d). Likewise,
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atorvastatin had minimal effects on CD4+ T cell activation pro-
ﬁles based on the expression of the cell surface markers CD69 or
CD25 (Supplementary Figure 4e and 4f).
Statins have previously been reported to alter Th effector cell
responses32,33, so we next determined the effect of atorvastatin on
the expression proﬁle of IL-17 and tumour necrosis factor-α
(TNFα) in Th1 switching cells. While the results showed a
decrease in the frequency of IL-17+IL-10+ and TNFα+IL-10+
cells with atorvastatin treatment, we documented a concomitant
increase in IL-17 and TNFα single-positive populations that did
not express IL-10 (Fig. 2e and Supplementary Figure 4g). Once
again these effects were reversed by MA supplementation. During
analysis of the effects of statin on Th2 cytokine proﬁles, we were
unable to reliably detect intracellular IL-4 by ﬂow cytometry.
Instead, we measured secreted cytokine over the 36 h activation
period. Like IL-10, levels of IL-4 were also decreased in the
presence of atorvastatin (Fig. 3f), indicating that the effects of
CBP perturbation are not conﬁned to IL-10 expression, but may
also inﬂuence Th2 responses, while at the same time sparing or
even potentiating Th1 and Th17 effector cytokines.
To determine whether the effects of CBP perturbations on IL-
10 were speciﬁc for CD46-dependent induction, we examined the
effects of statin on α-CD3-stimulated CD4+ T cells co-cultured
with monocytes in the presence of adalimumab, a humanised α-
TNFα monoclonal antibody (mAb), as an alternative pathway to
IL-10 induction34,35. In keeping with the results above, we
documented dose-dependent inhibition of IL-10-producing
T cells, while the frequency of IFNγ+ cells remained unchanged
(Fig. 2g and Supplementary Figure 4h). Similar results were
obtained in an IFNα-dependent IL-10-inducing system12 when
cells were cultured in the presence of atorvastatin ±MA
(Supplementary Figure 4i). Together, these data further support
the notion that the CBP regulates IL-10 expression in human
CD4+ T cells.
IL-10 is not dependent on isoprenylation or vitamin D3. We
next set out to deﬁne more precisely which elements of the CBP
regulate IL-10. First, we ascertained that statins exerted their
inhibitory mechanism by targeting intracellular pathways through
a comparison of the effects of atorvastatin, mevastatin and pra-
vastatin. Similarly to atorvastatin, mevastatin is a lipophilic statin
preparation that diffuses across the membrane, while pravastatin
is lipophobic and cannot enter the cell in the absence of active
transport36,37. Similar inhibitory effects were observed on T cells
stimulated in the presence of mevastatin but not pravastatin
(Fig. 3a), demonstrating that statins mediate their IL-10 inhibi-
tory effects through mechanisms that require targeting of intra-
cellular pathways.
To unravel the speciﬁc branch of the CBP that regulates IL-10
expression, we cultured Th1 switching cells in the presence of
pharmacological inhibitors that target enzymes in the cholesterol
pathway (Supplementary Figure 2) and analysed IL-10 expres-
sion. Firstly, we tested whether atorvastatin inhibits IL-10 by
inhibiting isoprenylation. Isoprenylation regulates cell signalling
cascades, and targeted inhibition of the isoprenylation pathway is
known to alter cytokine expression patterns in vivo and in vitro32.
To this end, we incubated Th1 switching cells with inhibitors of
farnesyl-PP transferase (FTase I inhibitor), geranylgenaryltrans-
ferase I (GGTI-298) and Rab geranylgeranyl transferase (psoro-
mic acid) and assessed IL-10 expression. None of these
compounds exerted statin-like inhibitory effects on either the
frequency of IL-10+ cells (Fig. 3b) or its secretion (Supplementary
Figure 5a). In keeping with these ﬁndings, supplementation of
atorvastatin-treated cells with increasing concentrations of the
metabolites farnesyl-PP or geranylgeranyl-PP failed to rescue the
frequency of IL-10+ cells to those levels observed with MA
supplementation (Fig. 3c), a ﬁnding also conﬁrmed by enzyme-
linked immunosorbent assay (ELISA) (Supplementary Figure 5b).
Thus, the inhibitory effects of short-term atorvastatin exposure
do not appear to be related to perturbations of the isoprenylation
pathway.
The mevalonate pathway generates 7-dehydrocholesterol, the
precursor of vitamin D3, a metabolite that has been described as
key in the regulation of IL-10 in Th cells28. We therefore tested
whether inhibition of 7-dehydrocholesterol biosynthesis by the
small-molecule inhibitor U18666A would prevent Th1 switching
to IL-10. We observed a consistent reduction in IL-10 expression,
most notable at the highest concentration of inhibitor tested
(Fig. 3d and Supplementary Figure 5c). To address the speciﬁcity
of this effect, we supplemented T cell cultures with increasing
concentrations of calcitriol, the active metabolite of vitamin D3,
in the presence of 5 μM atorvastatin. At concentrations known to
induce IL-10 production in human CD4+ T cells28, calcitriol
failed to restore IL-10 levels to those achieved with MA at any
concentration (Fig. 3e and Supplementary Figure 5d), indicating
that deﬁciency of vitamin D3 is not responsible for the observed
regulation of IL-10 by statin treatment, and implicating other
U18666A targets, such as NCP138, in the regulation of IL-10.
We also ruled out the possibility that atorvastatin treatment
substantially altered the cellular lipid expression proﬁle. We
performed lipidomics analyses in Th1 switching cells treated with
different doses of atorvastatin with or without MA by liquid
chromatography mass spectrometry. We analysed the content of
536 lipid species covering the main lipid families (triacylglycer-
ides, sphingomyelins, phosphatidylcholines, phosphatidylserines,
ceramides) (Supplementary Data 2). PCAs of the dataset revealed
that samples clustered by donor rather than treatment (Supple-
mentary Figure 5e), indicating that in our system statins are not
substantially perturbing the levels of these lipid species within the
timeframe of the experiments. Of note, cholesterol levels were not
changed in the presence of atorvastatin (Fig. 3f). These data
suggested that perturbations of the whole metabolic pathway,
Fig. 2 T-helper type 1 (Th1) switching to interleukin-10 (IL-10) is blocked when the mevalonate pathway is inhibited. Puriﬁed human CD4+ T cells
stimulated in vitro with plate-bound α-CD3 (2 μgml−1)+ α-CD46 (5 μgml−1) and recombinant human interleukin-2 (rhIL-2) (50 Uml−1) were cultured for
36 h in the presence of atorvastatin and 250 μM mevalonic acid (MA) as indicated, unless stated otherwise. a Representative ﬂow cytometric analysis of
intracellular interferon-γ (IFNγ) and IL-10 staining. b Normalised frequency of IFNγ−IL-10+- (left), IFNγ+IL-10+- (centre) and IFNγ+IL-10−- (right)
producing cells (n= 20). c Normalised concentration of secreted IL-10 (n= 19). d Normalised IL10 messenger RNA (mRNA) levels (n= 8). e
Representative ﬂow cytometric analysis of intracellular IL-17 (top) and tumour necrosis factor-α (TNFα) (bottom) co-stained with IL-10 of atorvastatin-
treated cells (cumulative data shown in supplementary Fig. 3g). f Normalised concentration of secreted IL-4 (n= 9). g Effect of atorvastatin (AT)
treatment on puriﬁed CD4+ cells co-cultured with monocytes and α-CD3 (100 ngml−1) in the absence or presence of Adalimumab (1 μgml−1). Data show
a representative dot-plot for intracellular IL-10 and IFNγ production (cumulative data shown in Supplementary Fig. 3h). Graphs show independent donors
(dots) normalised to 0 μM dose of atorvastatin; bars represent median values. *<0.05, **<0.01 and ***<0.001 denote a signiﬁcant difference compared to
untreated cells by repeated-measures one-way analysis of variance (ANOVA) test with post hoc Dunnett’s correction (b, d, f) or Friedman test with post
hoc Dunn’s correction (c)
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rather than a speciﬁc metabolite, might be responsible for the
reduction in IL-10 in Th1 switching cells.
25-HC alters cholesterol homeostasis. A failure to regulate IL-10
expression via manipulation of pathway branch points described
above, such as those linked to isoprenylation or vitamin D bio-
synthesis, provided the ﬁrst clues that intact cholesterol ﬂux may
be a key requirement for robust Th1 switching39. To test whether
coordinate reduction in levels of CBP enzymes would be sufﬁcient
to uncouple IL-10 production from the Th1 switching
programme, we studied the effects of 25-HC supplementation in
our culture system. 25-HC is an immune oxysterol derived from
cholesterol that is abundantly secreted by activated macrophages
and is known to control cholesterol ﬂux by inhibiting 3-hydroxy-
3-methylglutaryl-CoA reductase and the SREBP-2 pathway,
responsible for the transcriptional regulation of the CBP
machinery (Supplementary Figure 2)29,30. First, we addressed if
increasing concentrations of 25-HC within the physiological
range would exert a negative effect on CBP homeostasis during
Th1 switching by measuring key CBP enzymes known to be
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regulated by SREBP-2 and which we had also determined to be
related to IL-10 switching (Fig. 1b and Supplementary Figure 2).
Expression of LDLR, HMGCS1, FDFT1 and DHCR7 were
downregulated at the mRNA level in a dose-dependent manner
when cells were exposed to 25-HC for the 36 h incubation period
(Fig. 4a). These data demonstrate that 25-HC perturbs CBP
homeostasis in CD4+ T cells. Unexpectedly, supplementation of
25-HC-treated cultures with cholesterol restored the levels of
SREBP-2 target genes (Supplementary Figure 6a). This observa-
tion suggests that cholesterol interferes with 25-HC regulation of
SREBP-2 transcriptional activity in our system.
We next investigated how 25-HC regulates IL-10 expression. In
agreement with our hypothesis, supplementation of
Th1 switching cells with increasing concentrations of 25-HC
led to a dose-dependent inhibition of IL-10 expression as
determined by ﬂow cytometry (Fig. 4b, c) and by quantiﬁcation
of secreted protein levels (Fig. 4d), while the levels of IFNγ
remained unchanged (Fig. 4b, c). The speciﬁc suppression of IL-
10 expression by 25-HC was also observed in other IL-10-
inducing in vitro systems (Supplementary Figure 6c and 6d)12,34.
To further verify the requirement of cholesterol ﬂux in IL-10
expression, we performed experiments in which cells were
cultured either under sub-optimal lipid conditions (media
supplemented with delipidised serum, or lipid-free media) or
where cultures were supplemented with cholesterol. Culturing
cells in lipid-free media had a signiﬁcant impact on down-
regulating IL-10 expression, while IFNγ levels remained
unchanged (Fig. 4e). Supplementation with cholesterol had no
additive effect on IL-10 expression in cells cultured in standard
media conditions. However, when cholesterol was added back to
cultures in the presence of high 25-HC concentrations,
Th1 switching to IL-10 was fully restored (Fig. 4e), while
supplementation with MA did not prevent the inhibitory effects
of 25-HC on IL-10 expression levels (data not shown). Taken
together, these data demonstrate that inhibition of Th1 switching
by 25-HC is linked to inhibition of cholesterol ﬂux through
similar mechanisms to those described in innate immune cells30
and that optimal cholesterol homeostasis is a requirement for
adequate IL-10 expression by human CD4+ T cells.
Cholesterol metabolism regulates c-Maf expression. Because
our data suggested that CBP regulates IL-10, at least in part, at the
transcriptional level (Fig. 2d), we set out to identify the tran-
scription factor/s that might be responsible for the CBP-mediated
IL-10 downregulation, reasoning that CBP ﬂux regulates factors
directly involved in the transcriptional regulation of IL-10. To test
this hypothesis, we cultured Th1 switching cells in the presence
of increasing concentrations of 25-HC and measured MAF,
the gene that encodes for the transcription factor c-Maf,
considered as the master transcription regulator for IL-10 in
CD4+ T cells10,15,17,40. Blockade of the CBP with 25-HC reduced
MAF mRNA levels in a dose-dependent manner (Fig. 5a).
However, mRNA levels of PRDM1, which encodes the tran-
scription factor Blimp-1 and which has recently been implicated
in sterol-mediated regulation of IL-10 in mouse CD4+ T cells41,
did not change with 25-HC treatment (Fig. 5b). Downregulation
of MAF at the mRNA level was also evident at the protein level
(Fig. 5c, d) and this was prevented upon supplementation of
cultures with cholesterol (Fig. 5e). Moreover, there was a strong
correlation between the protein levels of IL-10 and c-Maf
(Fig. 5f), suggesting that these events are related.
Cholesterol ﬂux predicts progression to inﬂammatory disease.
The data above demonstrated that alterations in the CBP regulate
pathways linked to immune resolution, at least in vitro, raising
the possibility that perturbations in cholesterol ﬂux could pro-
mote the inﬂammatory response in human disease. To explore
this in an in vivo context, we tested the hypothesis that expression
of CBP genes in synovial tissue biopsies from subjects at high risk
of developing RA could predict disease outcome. Speciﬁcally, we
reasoned that high levels of cholesterol-25-hydroxylase (CH25H),
the enzyme that synthesises 25-HC from cholesterol, would be
associated with failure to resolve inﬂammatory responses and
progression to clinically apparent inﬂammatory arthritis. To this
end, we interrogated gene expression proﬁling data from an
exploratory prospective study in which synovial tissue biopsies we
obtained from 13 autoantibody-positive arthralgia patients
deemed to be “at risk” of developing RA42,43. Over a median
follow-up time of 20 months (interquartile range (IQR) 2–44) six
individuals developed RA, while seven individuals did not
develop RA over a median follow-up time of 85 months (IQR
69–86). The wide IQR for developing disease reﬂects the variable
progression rates (i.e. time to develop arthritis from baseline). We
stratiﬁed the RA-risk group into low and high expressers
according to synovial CH25H mRNA expression. All high-risk
individuals who progressed to inﬂammatory arthritis displayed
high mRNA levels of CH25H, while the CH25Hlo group remained
arthritis free for the duration of follow-up (Fig. 6a, left; hazard
ratio (HR) 5.3, 95% conﬁdence interval (CI) 1.0, 27.9; P= 0.047).
Further analysis revealed that disease outcomes could also be
stratiﬁed according to synovial expression of DHCR7 (Fig. 6a,
centre, HR 8.9, 95% CI 1.6, 48.7; P= 0.012) and FDFT1 (Fig. 6a,
right, HR 14.5, 95% CI 2.7, 78.7; P= 0.002). In contrast to
CH25H, low expression of these CBP enzymes was found to be
associated with low IL-10 expression during Th1 switching, and
was found to be associated with arthritis development. Despite
the limitations of this small sized-study, these data support a
model in which perturbations of cholesterol ﬂux indicators are
linked to disease progression during the earliest detectable phase
of pathological inﬂammatory responses in vivo.
Fig. 3 Interleukin (IL-10) regulation in T-helper type 1 (Th1) switching cells is not dependent on isoprenylation, vitamin D3 or cellular cholesterol content.
Puriﬁed human CD4+ T cells stimulated in vitro with plate-bound α-CD3 (2 μgml−1)+ α-CD46 (5 μgml−1) and recombinant human interleukin-2 (rhIL-2)
(50Uml−1) were cultured for 36 h in the presence of selected metabolites and inhibitors as indicated. a Representative ﬂow cytometric analysis of
intracellular interferon-γ (IFNγ) and IL-10 staining of cells treated with different formulations of statin (data representative of three independent donors). b
Normalised frequency of IL-10+ cells cultured in the presence of inhibitors for farnesyl-PP transferase (FTase I inhibitor) (left) (n= 4), geranylgenaryl
transferase I (GGTI-298) (centre) (n= 4) and Rab geranylgeranyl transferase (psoromic acid) (right) (n= 5). c Normalised frequency of IL-10+ cells
cultured with 5μM atorvastatin (AT) and increasing concentrations of farnesylpyrophosphate (FPP) (left) and geranylgeranylphyrophosphate (GGPP)
(right) and mevalonic acid (MA) as control (n= 5). d Normalised frequency of IL-10+ cells cultured in the presence of increasing concentrations of
U18666A (n= 6). e Normalised frequency of IL-10+ cells cultured with 5 μM atorvastatin (AT) and increasing concentrations of calcitriol and mevalonic
acid (MA) as a control (n= 5). f Normalised total cellular cholesterol content measured by liquid chromatography mass spectrometry. The [cholesterol
–H2O+H]+ ion was the dominant adduct for cholesterol and relative intensity is shown for this ion (n= 3). Graphs show independent donors (dots)
normalised to 0μM dose of atorvastatin; bars represent median values. *<0.05 denote a signiﬁcant difference compared to untreated cells by Friedman test
with post hoc Dunn’s correction (d)
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Fig. 4 Interleukin (IL-10) expression in T-helper type 1 (Th1) switching cells is dependent on intact cholesterol pathway ﬁtness. Puriﬁed human CD4+
T cells stimulated in vitro with plate-bound α-CD3 (2 μgml−1)+ α-CD46 (5 μgml−1) and recombinant human interleukin-2 (rhIL-2) (50 Uml−1) were
cultured for 36 h in the presence of 25-hydroxycholesterol (25-HC). a Normalised LDLr, HMGCS1, FDFT1 and DHCR7 messenger RNA (mRNA) levels
(n= 6–7). b Representative ﬂow cytometric analysis of intracellular interferon-γ (IFNγ) and IL-10 staining. c Normalised frequency of IFNγ−IL-10+- (left),
IFNγ+IL-10+- (centre) and IFNγ+IL-10−- (right) producing cells (n= 16). d Normalised concentrations of secreted IL-10 (n= 9). e Normalised frequency of
IFNγ−IL-10+- (left), IFNγ+IL-10+- (centre) and IFNγ+IL-10−- (right) producing cells cultured under lipid-free medium (LFM), fully supplemented medium
(M) and cholesterol (500×) (Ch) in the presence or absence of 25-HC (2μM) for 36 h (n= 7). Graphs show independent donors (dots) normalised to
untreated cells; bars represent median values. *<0.05, **<0.01 and ***<0.001 denote a signiﬁcant difference compared to untreated cells by Friedman test
with post hoc Dunn’s correction (a, c: IFNγ−IL-10+, e) or by repeated-measures one-way analysis of variance (ANOVA) test with post hoc Dunnett’s
correction (c: IFNγ+IL-10+ and IFNγ+IL-10−, d)
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Discussion
Tight control of immune effector responses promotes home-
ostasis and health. Active acquisition of a resolution phase by
effector T cells, through induction of IL-10 expression, is critical
to this process2. Here, we undertook a systematic and unbiased
approach to uncover novel pathways that control resolution of
immune responses within the human CD4+ T cell compartment
and discovered that IL-10 is metabolically regulated by the CBP
in human CD4+ T cells. Our experiments have shown that per-
turbation of cholesterol biosynthesis by statins or 25-HC leads to
highly speciﬁc inhibition of IL-10 expression, an effect that was
reversed upon metabolite supplementation. Moreover, our data
uncovered a role for the CBP in controlling c-Maf expression,
since uncoupling of the pathway decreased expression of this
transcription factor, a master regulator of IL-10 expression in
immune cells40.
Unsupervised analysis revealed that the CBP is intimately
linked to IL-10 expression in primary human CD4+ T cells. In
keeping with these ﬁndings, blockade of the pathway with statins
in in vitro culture showed a robust inhibition of IL-10 expression,
pointing to a novel and unexpected anti-resolution effect of the
drug during Th1 switching. The effects of statins on immune and
inﬂammatory responses are conﬂicting. On the one hand, phar-
macological inhibition of cholesterol biosynthesis with statins
has been reported to have predominantly anti-inﬂammatory
effects44–46. In keeping with this, murine effector CD4+ T cells
treated with statins secrete less IFNγ and more IL-447,48 by
reducing biosynthesis of isoprenoids32. On the other hand, a
more pro-inﬂammatory role has been reported, where statins
increase IFNγ and TNFα secretion33,49, independent of cell
cholesterol content33, while other studies have reported reduced
IL-10 expression in both human and murine T cells upon
exposure to statins50–52. In our experiments, short-term exposure
(36 h) to atorvastatin was sufﬁcient to uncouple IFNγ and IL-10
production during Th1 switching without discernible effects on
cell proliferation, cell viability, isoprenylation or cellular lipid
content. This leads us to conclude that blocking the transition to
IL-10 expression is one of the earliest consequences of a change in
ﬂux along the CBP, and to speculate that IL-10 may not be
regulated by the actions of a speciﬁc metabolite, but linked to
states of metabolic ﬂux through the cholesterol pathway.
Further evidence to support the altered cholesterol metabolic
ﬂux model is the observation that immune oxysterols also inhibit
Th1 switching, since it is known that 25-HC reduces cholesterol
ﬂux in T cells by blocking the nuclear translocation of SREBP-230,
hence blocking the transcription of key components of the CBP,
an effect that we have also reported here. The production of 25-
HC is tightly regulated, and produced in the endoplasmic reti-
culum upon induction of CH25H29. The enzyme is strongly
upregulated by type I IFN in myeloid cells53 and plays a key role
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Fig. 5 Cholesterol biosynthesis pathway inhibition interferes with c-Maf expression. Puriﬁed human CD4+ T cells stimulated in vitro with plate-bound
α-CD3 (2 μgml−1)+ α-CD46 (5 μgml−1) and recombinant human interleukin-2 (rhIL-2) (50 Uml−1) were cultured for 36 h in the presence of 25-
hydroxycholesterol (25-HC). a Expression levels of MAF mRNA (n= 7). b Expression levels of PRDM1 mRNA (n= 6). c Representative ﬂow cytometric
analysis of intracellular c-Maf staining. d Normalised frequency of c-Maf+ cells (n= 16). e Normalised frequency of c-Maf+ cells cultured under fully
supplemented medium (M) and cholesterol (500×) (Ch) in the presence or absence of 2μM 25-HC (n= 3). f Correlation between frequency of c-Maf+
and IL-10+ cells, numbers denote r and p values for Spearman's correlation test. Graphs show independent donors (dots) normalised to untreated cells;
bars represent median values. *<0.05 and **<0.01 denote a signiﬁcant difference compared to untreated cells by Friedman test with post hoc Dunn’s
correction (a) or by repeated-measures one-way analysis of variance (ANOVA) test with post hoc Dunnett’s correction (d)
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in the anti-viral response. Interestingly, the production of 25-HC
and the expression of CH25H have been reported recently in
adaptive immune cells41. Strikingly, 25-HC produced by mouse
CD4+ T cells inhibited IL-10 expression in these cells by reducing
the expression of the transcription factor Blimp-141, a change that
we did not detect in human CD4+ T cells. This report conﬁrms
our observation that oxysterols regulate the expression of IL-10 in
CD4+ T cells, although via a different transcriptional mechanism,
providing evidence of differences in the IL-10 regulatory
mechanisms between mouse and human.
As CBP perturbation signiﬁcantly reduced IL10 mRNA levels,
we hypothesised that transcription factors reported to regulate IL-
10 expression were also metabolically regulated. c-Maf has been
described as the master transcription factor that drives Th2
cytokines, including IL-10, in CD4+ T cells13,17 and more
recently in Tregs54. Our results show that perturbations in CBP
affect c-Maf levels in the same way as IL-10, suggesting that c-Maf
might acts as a molecular platform that links metabolism and
immune resolution. In keeping with these ﬁndings was the
observation that statin treatment blocks IL-4 secretion. Deﬁning
the molecular link between c-Maf and cholesterol metabolism
requires more investigation, but consistent with our observations,
small members of the Maf family have been shown to form
heterodimers with the active form of the transcription factor
nuclear factor erythroid-derived 2-related factor 155 recently
described as a cholesterol sensor in the endoplasmic reticulum56.
Moreover, chromatin immunoprecipitation deep sequencing
approaches to identify SREBP-2 binding sites have revealed Maf
family members as potential targets57, providing a potential
molecular link between Maf family members and the CBP.
We believe that our ﬁndings shed light on disease mechanisms
that may extend beyond regulation of Th1 switching at the cel-
lular level. Firstly, IFN-inducible gene signatures have been
identiﬁed during the early phase of immune-mediated inﬂam-
matory diseases61,62, and so it is conceivable that IFNα-induced
CH25H/25-HC plays a key role in the initiation and persistence
of inﬂammatory responses by uncoupling IL-10-dependent
resolution. Secondly, the links between statin use and infection
or cancer have been attributed to their lipid-lowering effects
or to attenuation of the prenylation branch, leading to pertur-
bations in cell proliferation and signalling. Here, we offer an
alternative but not mutually exclusive mechanism for enhanced
host and anti-tumour immunity, underpinned by the capacity
of T cells to generate more IFNγ relative to IL-10. Finally,
clinical trials of biological therapy in patients with RA have
demonstrated reduced serum cholesterol levels associated with
active inﬂammatory disease, and increases in lipids in patients
responding to TNF inhibitors, as the inﬂammation resolves. This
observation, the so-called “lipid paradox”, has been linked to
chronic inﬂammatory states58, and initially raised concerns
about the risks of cardiovascular comorbidity with long-term
biological therapy. It is conceivable that rather than increasing
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Fig. 6 Messenger RNA (mRNA) levels of cholesterol biosynthesis pathway (CBP) enzymes are related to disease progression in man. a Expression levels of
cholesterol-25-hydroxylase (CH25H), FDFT1 and DHCR7 obtained from a gene expression proﬁling study of synovial biopsies from 13 rheumatoid arthritis (RA)-
risk individuals who were followed over time to investigate the development of arthritis. RA-risk individuals were stratiﬁed into relative low or high expressers
for the indicated genes, after which their arthritis-free survival was compared using a log-rank (Mantel–Cox) test. Graphs display arthritis-free survival curves
including the 95% conﬁdence interval (CI). b Schematic representation of interleukin-10 (IL-10) regulation by the cholesterol biosynthesis pathway. Normal
cholesterol pathway activity is required for adequate transcription of the IL10 gene and IL-10 expression in T-helper effector cells (left); when the ﬂux is reduced
via statin or 25-hydroxycholesterol (25-HC) supplementation, c-Maf expression is downregulated and IL-10 gene transcription reduced
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cardiovascular risk, increased serum cholesterol and cellular
cholesterol ﬂux contribute to mechanisms whereby TNF blockade
increases IL-10 production by T cells34,59. Conversely, rare
monogenic diseases that result in substantial reduction of cho-
lesterol biosynthesis, such as mevalonate kinase deﬁciency, are
characteristically inﬂammatory60,61, providing another link
between cholesterol metabolism and inﬂammatory responses.
The mechanisms whereby perturbation of cholesterol bio-
synthesis blocks IL-10 and c-Maf expression remain to be
determined. It will also be important to discern whether the
mechanism is common to all IL-10-expressing cell subsets, or is
unique to CD4+ T cells. This knowledge can then be used as a
framework to explore in relevant models the immunomodulatory
properties of small-molecule inhibitors and metabolites that
regulate cholesterol ﬂux. Experience to date demonstrates that the
CBP is drug-able. This opens up new therapeutic avenues to re-
purpose existing drugs, as well as develop new ones, for ﬁne-
tuning the sterol pathway according to whether the therapeutic
goal is to prevent chronic inﬂammation, or to promote host or
tumour immunity.
Methods
Cell puriﬁcation and culture. CD4+ T cells were positively isolated from density
gradient centrifugation (Lymphoprep, Axis-Shield) preparations of peripheral
blood mononuclear cells obtained from healthy volunteers (approval REC06/
Q0705/20 obtained from Bromley Research Ethics Committee) and NC24 CD
Leucocyte Cones (NHS Blood and Transplant) using CD4 microbeads (Miltenyi
Biotec) following the manufacturer’s recommendations. Purity of CD4+ cells was
routinely tested as >98%. For inducing Th1 switching cells, CD4+ T cells were
cultured at 1.5 × 106 ml−1 in 48-well plates (3 × 105 cells per well) coated with
mAbs to CD3 (Clone OKT3, 2 μgml−1) and CD46 (clone TRA-2-10, 5 μgml−1)
both from BioLegend18. Cells were cultured in RPMI-1640 containing 2 mM
L-glutamine and 0.1 g l−1 sodium bicarbonate (Sigma) supplemented with 10 mM
HEPES (PAA), 100 Uml−1 penicillin+ 0.1 mgml−1 streptomycin (PAA) and 10%
foetal bovine serum (Sigma) (fully supplemented media) or 10% lipid depleted
foetal bovine serum (Biowest) (lipid-free media), in the presence of 50 Uml−1 of
recombinant human IL-2 (Proleukin, Novartis). Where indicated, cells were cul-
tured in the presence of atorvastatin (Calbiochem), (R)-MA lithium salt (Sigma),
mevastatin (Sigma) (kindly donated by Dr. P. Vantourout), pravastatin (Sigma),
FTase I inhibitor (Calbiochem), GGTI-298 (Calbiochem), psoromic acid (Santa
Cruz Biotechnology), farnesylpyrophosphate ammonium salt (Sigma), ger-
anylgeranyl pyrophosphate ammonium salt (Sigma), U18666A (Sigma), 1α,25-
dihydroxyvitamin D3 (calcitriol) (Sigma), 25-hydroxycholesterol (Avanti lipids)
and/or “soluble” cholesterol (SyntheChol® NS0 Supplement, Sigma). Carrier/dilu-
ent controls were performed and no differences in cell viability were detected (data
not shown)62. Doses of cholesterol pathway inhibitors and metabolites have been
previously reported as active in in vitro experiments using human cells62–64. For
isolation of cytokine-producing populations, activated cells were stained with both
IL-10 and IFNγ Cytokine Secretion Assay kit (Miltenyi Biotec) following the
manufacturer’s protocol. Cytokine-positive cells were consequently FACS sorted
using a FACS Aria (BD Biosciences). For adalimumab experiments, CD4+ T cells
and CD14+ monocytes (1 × 106 ml−1) were co-cultured with 100 ng ml−1 CD3
mAb and 1 μgml−1 adalimumab (Abbott) for 3 days34,35. For IFNα-inducing
experiments, CD4+ T cells (2.5 × 106 ml−1) were cultured with plate-bound CD3
(0.5 μgml−1), soluble CD28 (clone CD28.2, BD Biosciences, 1 μgml−1) and IFNα
2a (PBL Assay Science, 600 Uml−1) for 3 days12. Informed, written consent was
obtained from all donors.
Microarray. For primary cell experiments, cell pellets for mRNA isolation were
lysed in Trizol (Ambion, Life Technologies) and RNA extracted by guanidium-
isothiocyanate phenol/chloroform extraction method following the manufacturer’s
instructions. Total RNA was quantiﬁed using the Nanodrop ND1000 and RNA
integrity assessed with the Agilent Bioanalyzer 2100 using the RNA 6000 Nano
Chips. One hundred nanograms of total RNA was used to prepare the targets,
using the 3′ IVT Express kit (Affymetrix) in accordance with the manufacturer’s
instructions. Hybridisation cocktails were hybridised onto the Human Genome
U133 plus2 gene chip (Affymetrix). For Jurkat cell line experiments, three technical
replicates of Jurkat T cell stably expressing CYT-1 or CYT-2 and untransduced
cells as control were analysed. RNA was converted to cDNA using the Ovation®
Pico WTA Systems V2 and labelled using the Encore® BiotinIL Module (NuGen)
according to the manufacturers recommendations. Labelled cDNA was hybridised
onto Illumina HT12v4 arrays (Illumina).
Flow cytometry assays and intracellular staining. After the indicated culture
time, cells were harvested. Surface staining for activation markers was performed
with CD69 (clone FN50) and CD25 (clone M-A251), both from BioLegend, after
staining with Fixable Viability Dye eFluor780 (eBiosciences) to exclude dead cells.
For intracellular staining of cytokines, cells were restimulated for 3 h with phorbol
myristate acetate (50 ng ml−1) and ionomycin (1μM) (Sigma) in the presence of
Brefeldin A and GolgiStop (1000×, BD Biosciences). After stimulation, cells were
stained with Fixable Viability Dye eFluor780 (eBiosciences), ﬁxed in 4% paraf-
ormaldehyde solution (Electron Microscopy Sciences) and permeabilised in 0.1%
saponin (Sigma) solution for intracellular staining with the following antibodies:
IL-10 (clone JES3-9D7); IFNγ (clone 4S.B3); TNFα (clone Mab11) and IL-17 (clone
BL168), all from BioLegend. For intracellular staining of c-Maf (clone sym0F1 from
eBiosciences), the transcription factor staining buffer set from eBiosciences was
used, following the manufacturer’s instructions. FACS ﬁles were acquired on a
FACS Canto (BD Biosciences) and analysed using the FlowJo software (TreeStar).
Doublets and cells positive for Fixable Viability Dye eFluor780 were excluded from
analyses. Apoptosis was assessed by Annexin V staining (BD Biosciences) on
treated cells following the manufacturer’s protocol. Cell proliferation measure-
ments were performed on cell trace violet (Invitrogen) stained cells following
the manufacturer’s protocol, after 36 h of incubation with plate-bound CD3 and
CD46 or beads coated with CD3 and CD28 (Gibco) at 1:10 ratio in the presence of
50Uml−1 of IL-2.
Detection of soluble cytokines. Cell culture supernatants were collected and
stored at −20 °C until analysed. Cytokine levels were measured using speciﬁc
ELISA kits for human IFNγ and IL-10 (R&D Systems) following the manu-
facturer’s speciﬁcations. Colorimetric determinations were transformed into con-
centrations via interpolation of standard curves using a four-parameter logistic
curve ﬁt. For IL-4 measurements, a BD Cytometric Bead Array kit (BD Bios-
ciences) was used and data were analysed according to the manufacturer’s protocol.
Quantitative real-time PCR. Cell pellets for mRNA isolation were lysed in Trizol
(Ambion, Life Technologies) and RNA was extracted by guanidium-isothescyanate
phenol/chloroform extraction method following the manufacturer’s protocols.
Total RNA was quantiﬁed using the Nanodrop ND1000. Normalised RNA
quantities were reverse transcribed into cDNA using the qPCRBIO Synthesis kit
(PCR Biosystems). qPCR was performed in qPCRBIO Probe Mix (PCR Biosys-
tems) using pre-validated FAM-labelled Taqman Gene Expression Assays for LDLr
(Hs00181192_m1), HMGCS1 (Hs00940429_m1), FDFT1 (Hs00926054_m1) and
DHCR7 (Hs01023087_m1), IL10 (Hs00961622_m1), MAF (Hs04185012_s1) and
PRDM1 (Hs00153357_m1). The reactions were multiplexed using VIC-labelled 18S
probe (Applied Biosystems), which was used for normalisation of Ct values. The
reactions were run using the ABI Prism 7700 Sequence Detection System (Applied
Biosystems). Ct values were determined using the SDS software (Applied Biosys-
tems) and gene expression levels were determined according to the dCt method
(relative abundance= 2(−dct)).
Mass spectrometry assays. Cell pellets were prepared from Th1 switching cells
with the appropriate treatment. Lipids were extracted from cells by liquid–liquid
extraction in chloroform:methanol:water (2:1:1, v/v) using Folch’s method65. The
organic layer was removed, dried down under nitrogen and reconstituted in 15 mM
ammonium acetate in isopropanol:methanol (2:1). An internal standard mix
containing isotopically labelled lipids across several lipid classes was added. Sam-
ples were infused using a Triversa Nanomate® (Advion BioSciences, Ithaca, NY,
USA), with capillary voltage 1.4 kV, 0.3 gas ﬂow for 1 min into an LTQ Orbitrap
Elite™ (Thermo Fisher Scientiﬁc). Spectra were acquired in positive and negative
mode, from 200 to 1000m/z. Data were converted to mzML format for subsequent
data processing, and features were picked using an in-house R script. Lipid identity
was performed by accurate mass using the LipidMaps database66. Basal levels of
lipids for each donor were subtracted prior to multivariate statistical analysis. PCA
was performed using SIMCA 14 (Umetrics, Sweden), following normalisation to
cell count and internal standard, and Pareto scaling.
Synovial biopsy study. Within the framework of another research study43
(manuscript in preparation), an explorative genome-wide transcriptional proﬁling
study was performed on synovial tissue biopsies obtained from 13 autoantibody-
positive (IgM rheumatoid factor and/or anti-citrullinated protein antibody)
arthralgia patients using Agilent arrays (Agilent technologies, Amstelveen, The
Netherlands). The study was approved by the institutional review board of the
Academic Medical Center (Amsterdam, The Netherlands), and all study subjects
gave written informed consent. At the time of synovial biopsy of a knee joint by
mini-arthroscopy these individuals did not display any evidence of arthritis as
assessed by an experienced rheumatologist. However, they are “at risk” for
developing RA and therefore prospectively followed over time to study the possible
development of arthritis42. Expression levels of genes of interest were extracted
from this dataset and investigated for their possible association with arthritis
development. To this end, RA-risk individuals were stratiﬁed based on their mRNA
levels into relative low or high expressers compared to the median values of the
whole population, after which arthritis-free survival was compared to each other
using a log-rank (Mantel–Cox) test.
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Statistical analyses. For ﬂow cytometry, ELISA and qPCR data, statistical ana-
lyses were performed in GraphPad Prism. First, normality of data distribution of
either raw or transformed data was analysed by performing a D’Agostino and
Pearson omnibus normality test. Normally distributed data was compared with
repeated-measures one-way analysis of variance test with post hoc Dunnett’s
correction for multiple comparisons to cells with no treatment. When data were
not normally distributed, a Friedman test with post hoc Dunn’s multiple com-
parison correction was applied. When the N was too small to pass a normality test
(n < 8), a non-parametric test was performed and post hoc power calculations were
performed to conﬁrm signiﬁcance. Differences were considered signiﬁcant at the
95% conﬁdence level.
Microarray data analysis. Raw data were summarised and normalised using
Robust Multi-array Average. Probes without an annotated HUGO gene symbol
were removed from the analysis. Probes with a normalised standard deviation
(σ/σmax) lower than 0.05 were removed from the analysis. Differential expression
comparisons between the IFNγ+IL-10−, IFNγ+IL-10+ and IFNγ−IL-10+ popu-
lations was computed using Limma taking into account the correlation between
samples from the same subject. No variance ﬁlter was applied. The following model
was ﬁt: ‘“expr ~ population+ sex”’. For each comparison of interest, contrasts were
extracted using the makeContrasts function in the R package Limma. P values were
corrected for multiple testing across all genes using the Benjamini–Hochberg
procedure. Adjusted P values lower than 0.05 were considered signiﬁcant. Clus-
tering analysis was performed using k-means (as implemented in the R package
stat) on IFNγ+IL-10−, IFNγ+IL-10+ and IFNγ−IL-10+ populations. The number
of clusters was set to three and the number of random initialisations was set to 10.
All probe sets were used for clustering. PCA was performed using the R function
prcomp from the package stat and the ﬁrst two components were used to visualise
the results of the clustering algorithm. Plots were created using the R package
ggplot2. Correlation between IL-10 protein expression and probe expression was
estimated using linear regression adjusting for gender. P values were corrected for
multiple testing using the Benjamini–Hochberg procedure. Corrected P values
lower than 0.05 were considered signiﬁcant. Pathway analysis was performed on
the list of signiﬁcantly correlated probes using Ingenuity Pathway Analysis. For
Jurkat T cell microarray analyses, results were compiled using Genome Studio
(illumine) where they were normalised using quantile normalisation and pathway
analyses performed as above.
Data availability
The data generated for this work have been deposited at Gene Expression Omnibus
(GEO) under the accession codes GSE119416 and GSE122499. All other data
supporting the ﬁndings of this study that are not included in the ﬁgures or the
supplementary information of this paper are available from the corresponding
authors upon reasonable request.
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